pubmed.ncbi.nlm.nih.gov

Mitochondrial Redox Hubs as Promising Targets for Anticancer Therapy - PubMed

  • ️Wed Jan 01 2020

Review

Mitochondrial Redox Hubs as Promising Targets for Anticancer Therapy

Luigi Ippolito et al. Front Oncol. 2020.

Abstract

Mitochondria play multifaceted roles in malignant tumor progression. Beyond their bioenergetic role, mitochondria are essential for providing malignant cells a higher plasticity to face the harsh environmental conditions. Cell-autonomous metabolic deregulation of cancer cells, or metabolic adaptation to microenvironmental cues (lack of nutrients, stromal supply, hypoxia, etc.), represent the triggering event of mitochondria overexploitation to orchestrate nutrient sensing and upload, signaling, and redox circuits. As readout of their higher function, mitochondria produce high amounts of reactive oxygen species (ROS) that are functional for multiple signaling networks underlying tumor proliferation, survival, and metastatic process. To compensate for the higher rate of mitochondrial ROS production, cancer cells have evolved adaptive mechanisms to increase their antioxidant systems and to address ROS activating pathways useful for the tumor cell adaptation to environmental changes. As these properties are critical for cancer progression, mitochondrial ROS have recently become an attractive target for anti-cancer therapies. We discuss how understanding of mitochondrial function in the tumor-specific generation of ROS will impact on the development of novel redox-based targeted therapeutic strategies.

Keywords: ROS—reactive oxygen species; anti oxidant; anticancer activity; mitochondria; redox targeting; tumor microenviroment.

Copyright © 2020 Ippolito, Giannoni, Chiarugi and Parri.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Cell autonomous and cell non-autonomous mechanisms impact on the mitochondrial ROS (mROS) production and management in cancer cells.

Similar articles

Cited by

References

    1. Sullivan LB, Chandel NS. Mitochondrial reactive oxygen species and cancer. Cancer Metab. (2014) 2:17. 10.1186/2049-3002-2-17 - DOI - PMC - PubMed
    1. Costa NJ, Dahm CC, Hurrell F, Taylor ER, Murphy MP. Interactions of mitochondrial thiols with nitric oxide. Antioxid Redox Signal. (2003) 5:291–305. 10.1089/152308603322110878 - DOI - PubMed
    1. Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the Hallmarks of Cancer. Cancer Cell. (2018) 34:21–43. 10.1016/j.ccell.2018.03.022 - DOI - PMC - PubMed
    1. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, et al. . The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. (2010) 12:213–23. 10.1038/ncb2021 - DOI - PubMed
    1. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, et al. . Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. (2014) 514:628–32. 10.1038/nature13611 - DOI - PMC - PubMed

Publication types